For UK pharmaceutical and life sciences leaders
You need a senior UK commercial lead, but not a full-time one
A fractional model is not a cut-price hire, it is senior expertise applied to a defined scope for a defined period. Done correctly, it costs far less than a full-time executive while delivering the same strategic output.
Two minutes. Solva follows up with specific fractional leadership options.
- Prolonged vacancies in critical commercial leadership roles, leading to missed market opportunities
- Inconsistent or underdeveloped UK market access strategies for new healthcare products or services
- Overburdened existing leadership struggling to balance strategic growth with day-to-day operations
- Suboptimal commercial performance due to a lack of specialist expertise in key areas like pricing or key account management
- Delayed market entry or expansion for new healthcare offerings
- Inefficient commercial processes and lack of strategic direction
- Loss of potential revenue from untapped market segments or delayed product launches
- Higher recruitment costs and longer time-to-hire for permanent roles
- Perception of being slow to innovate or adapt in the competitive UK private healthcare market
- Difficulty attracting top-tier talent due to perceived organisational instability or lack of clear leadership
The UK fractional executive market has grown 45% year-over-year (Fractional-Csuite.com, 2026)
Frequently asked questions
Why does this problem persist?
The fractional model is misunderstood. It is not a cheaper version of a full hire. It is a different model, senior expertise applied to a defined scope, for a defined period, with a clear outcome.
What is the cost of leaving it unaddressed?
Fractional senior hires save 40-60% on executive-level labour costs compared to full-time hires (Executive Heads, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.